Nurix Therapeutics, Inc. (NRIX)

Over the past six months, Nurix Therapeutics' stock price has increased by 55.14%. Positive clinical data from the Phase 1a/1b study of bexobrutideg (NX-5948) at the ASH Annual Meeting showed promising efficacy and safety. Several investment banks upgraded Nurix's stock rating and raised price targets. Nurix outlined its 2026 objectives, focusing on advancing bexobrutideg through pivotal clinical trials. Nurix strengthened its financial position through an offering that provided $250 million in gross proceeds. Nurix actively participated in healthcare conferences to communicate its progress.

As a clinical-stage biopharmaceutical company, Nurix Therapeutics' products are still in development, and traditional demand seasonality is not directly applicable. Seasonal analysis for NRIX stock suggests a period of seasonal strength from March 30 to August 4, but four years of data is insufficient to create a reliable seasonal profile.

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule and antibody therapies. The company operates in the biotechnology and drug discovery industry, modulating cellular protein levels to treat cancer, inflammatory conditions, and other diseases. Nurix utilizes its DELigase Platform to develop targeted protein degradation medicines. Key products include NX-5948 (Bexobrutideg), an orally bioavailable BTK degrader in Phase 1B/2 clinical trials; NX-2127 (Zelebrudomide), an orally bioavailable BTK and IKZF1/3 degrader in Phase 1A clinical trials; NX-1607, an orally bioavailable CBL-B inhibitor in Phase 1A clinical trials; and NX 0479/GS-6791, an IRAK4 degrader being developed with Gilead Sciences, Inc.

Nurix Therapeutics Inc. has a presence in the United States, with its headquarters in San Francisco, California. It has R&D centers in Brisbane, California, and The Woodlands, Texas, supporting its R&D initiatives.

Nurix Therapeutics' brand reputation over the past year is largely positive, driven by clinical advancements and analyst sentiment. The company received analyst upgrades and increased price targets due to confidence in bexobrutideg. While the stock had fallen in early 2025 due to limited data catalysts, subsequent positive clinical data and strategic announcements have bolstered its reputation.

Nurix Therapeutics, Inc. is primarily owned by institutional shareholders, who hold approximately 110.27% of the stock. Insiders own about 11.02%, while retail investors hold a smaller percentage. Third Rock Ventures III LP is the largest individual shareholder.